PTPI vs MNKD vs LLY vs UTHR

For growth investors, Eli Lilly and Company (LLY) is the stronger pick with 44.

7% revenue growth year-over-year, versus -12. 2% for Petros Pharmaceuticals, Inc. (PTPI). United Therapeutics Corporation (UTHR) offers the better valuation at 20. 3x trailing P/E (19. 9x forward), making it the more compelling value choice. Analysts rate MannKind Corporation (MNKD) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, United Therapeutics Corporation (UTHR) is the cheapest at 20.

3x versus MannKind Corporation at 176. 0x. On forward P/E, United Therapeutics Corporation is actually cheaper at 19. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Eli Lilly and Company wins at 0. 91x versus United Therapeutics Corporation's 1. 03x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +399.

3%, compared to -100. 0% for Petros Pharmaceuticals, Inc. (PTPI). Over 10 years, the gap is even starker: LLY returned +1203% versus PTPI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), United Therapeutics Corporation (UTHR) is the lower-risk stock at 0.

21β versus Petros Pharmaceuticals, Inc. 's 1. 45β — meaning PTPI is approximately 600% more volatile than UTHR relative to the S&P 500.

By revenue growth (latest reported year), Eli Lilly and Company (LLY) is pulling ahead at 44.

7% versus -12. 2% for Petros Pharmaceuticals, Inc. (PTPI). On earnings-per-share growth, the picture is similar: Eli Lilly and Company grew EPS 96. 0% year-over-year, compared to -79. 4% for MannKind Corporation. Over a 3-year CAGR, MNKD leads at 51. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

United Therapeutics Corporation (UTHR) is the more profitable company, earning 41.

9% net margin versus -280. 1% for Petros Pharmaceuticals, Inc. — meaning it keeps 41. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UTHR leads at 47. 7% versus -345. 8% for PTPI. At the gross margin level — before operating expenses — UTHR leads at 87. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Eli Lilly and Company (LLY) is the more undervalued stock at a PEG of 0. 91x versus United Therapeutics Corporation's 1. 03x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, United Therapeutics Corporation (UTHR) trades at 19. 9x forward P/E versus 26. 3x for Eli Lilly and Company — 6. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MNKD: 134. 4% to $8. 25.

In this comparison, PTPI (100.

0% yield), LLY (0. 6% yield) pay a dividend. MNKD, UTHR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

65), 0. 6% yield, +1203% 10Y return). Both have compounded well over 10 years (LLY: +1203%, MNKD: -46. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PTPI is a small-cap income-oriented stock; MNKD is a small-cap high-growth stock; LLY is a large-cap high-growth stock; UTHR is a mid-cap quality compounder stock. PTPI, LLY pay a dividend while MNKD, UTHR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.